Filing Flows › Nektar Therapeutics (NKTR) › Recalls, complaints & regulation

Nektar Therapeutics (NKTR): clinical trials

Nektar Therapeutics (NKTR) beyond its filings: 3 active clinical trials.

Nektar Therapeutics' latest quarter

Nektar Therapeutics, Q2 2026: revenue $10.1M (-9% year over year), operating margin -417.9%, net loss $40.6M, operating cash flow −$75.8M. The chart follows the revenue to costs, profit and cash.

Questions

How many clinical trials does Nektar Therapeutics have?

3 active studies on ClinicalTrials.gov, 2 in phase 3.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.